|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
179,400,000 |
Market
Cap: |
199.13(M) |
Last
Volume: |
686,440 |
Avg
Vol: |
2,244,045 |
52
Week Range: |
$0.449 - $1.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
27,398 |
133,163 |
206,518 |
439,773 |
Total Sell Value |
$35,069 |
$211,063 |
$253,972 |
$733,404 |
Total People Sold |
3 |
5 |
5 |
9 |
Total Sell Transactions |
3 |
8 |
14 |
31 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-11-07 |
4 |
OE |
$25.51 |
$441,323 |
D/D |
17,300 |
58,233 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-11-07 |
4 |
OE |
$10.69 |
$184,937 |
D/D |
17,300 |
75,533 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-11-07 |
4 |
AS |
$25.78 |
$1,944,044 |
D/D |
(75,409) |
31,102 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-11-07 |
4 |
OE |
$9.53 |
$718,648 |
D/D |
75,409 |
106,511 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-11-06 |
4 |
AS |
$25.07 |
$128,283 |
D/D |
(5,117) |
58,233 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-11-06 |
4 |
OE |
$10.69 |
$54,701 |
D/D |
5,117 |
63,350 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-11-06 |
4 |
AS |
$24.98 |
$522,432 |
D/D |
(20,914) |
31,102 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-11-06 |
4 |
OE |
$9.53 |
$199,310 |
D/D |
20,914 |
52,016 |
|
- |
|
Robin Howard W |
President & CEO |
|
2017-11-01 |
4 |
AS |
$23.57 |
$1,964,182 |
D/D |
(83,334) |
152,504 |
|
- |
|
Robin Howard W |
President & CEO |
|
2017-11-01 |
4 |
OE |
$11.34 |
$945,008 |
D/D |
83,334 |
235,838 |
|
- |
|
Robin Howard W |
President & CEO |
|
2017-10-09 |
4 |
AS |
$24.20 |
$2,016,659 |
D/D |
(83,333) |
152,504 |
|
- |
|
Robin Howard W |
President & CEO |
|
2017-10-09 |
4 |
OE |
$11.34 |
$944,996 |
D/D |
83,333 |
235,837 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-10-05 |
4 |
AS |
$24.97 |
$1,090,615 |
D/D |
(43,677) |
31,102 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2017-10-05 |
4 |
OE |
$9.53 |
$416,242 |
D/D |
43,677 |
74,779 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-10-05 |
4 |
AS |
$25.00 |
$189,575 |
D/D |
(7,583) |
58,233 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2017-10-05 |
4 |
OE |
$10.69 |
$81,062 |
D/D |
7,583 |
65,816 |
|
- |
|
Labrucherie Gil M |
SVP & Chief Financial Officer |
|
2017-10-02 |
4 |
AS |
$24.45 |
$2,934,000 |
D/D |
(120,000) |
63,414 |
|
- |
|
Labrucherie Gil M |
SVP & Chief Financial Officer |
|
2017-10-02 |
4 |
OE |
$11.34 |
$1,360,800 |
D/D |
120,000 |
183,414 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2017-10-02 |
4 |
AS |
$24.21 |
$1,372,804 |
D/D |
(56,704) |
41,575 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2017-10-02 |
4 |
OE |
$11.04 |
$626,012 |
D/D |
56,704 |
98,279 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2017-09-29 |
4 |
AS |
$24.04 |
$1,040,836 |
D/D |
(43,296) |
41,575 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2017-09-29 |
4 |
OE |
$11.04 |
$477,988 |
D/D |
43,296 |
84,871 |
|
- |
|
Lingnau Lutz |
Director |
|
2017-09-22 |
4 |
AS |
$21.97 |
$109,850 |
D/D |
(5,000) |
27,450 |
|
- |
|
Kuebler Christopher A |
Director |
|
2017-09-22 |
4 |
AS |
$21.86 |
$87,440 |
D/D |
(4,000) |
40,500 |
|
- |
|
Chess Robert |
Director |
|
2017-09-21 |
4 |
AS |
$21.72 |
$139,008 |
D/D |
(6,400) |
274,223 |
|
- |
|
709 Records found
|
|
Page 18 of 29 |
|
|